Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes,
dc.contributor.author | Vinik, Aaron I. | en_US |
dc.contributor.author | Tsai, Shih-tzer | en_US |
dc.contributor.author | Moattari, Ali Reza | en_US |
dc.contributor.author | Cheung, Polly S. Y. | en_US |
dc.contributor.author | Eckhauser, Frederic E. | en_US |
dc.contributor.author | Cho, Kyung J. | en_US |
dc.date.accessioned | 2006-04-07T19:22:28Z | |
dc.date.available | 2006-04-07T19:22:28Z | |
dc.date.issued | 1986-12-22 | en_US |
dc.identifier.citation | Vinik, Aaron I., Tsai, Shih-tzer, Moattari, Ali Reza, Cheung, Polly, Eckhauser, Frederic E., Cho, Kyung (1986/12/22)."Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes,." The American Journal of Medicine 81(6, Supplement 2): 23-40. <http://hdl.handle.net/2027.42/25940> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TDC-4CJV6S9-H/2/7a261cb3a746f50d33a8d97823d837c3 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/25940 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2879447&dopt=citation | en_US |
dc.description.abstract | SMS 201-995 (Sandostatin) was studied using low doses (50 to 100 [mu]g) administered subcutaneously every 12 hours. A single 50-[mu]g dose of SMS 201-995 effectively controlled gastric acid and blood gastrin levels for 12 hours in three patients with benign gastrinomas and was useful in their perioperative management. Higher doses of the agent (500 to 800 [mu]g per day) had no effect on metastases in one of two patients with metastatic gastrinoma. In the other patient, one tumor shrank but the other continued to grow after three months of treatment while serum gastrin levels did not change. Cultured metastatic tumor tissue from this patient released different forms of gastrin; growth rates varied, independent of uptake of SMS 201-995, and gastrin release increased. A neonate with nesidioblastosis maintained normal blood glucose levels while receiving SMS 201-995 therapy following a 95 percent pancreatic resection. In two elderly patients with organic hypoglycemia--one with a single benign adenoma and one with multiple adenomatosis--the somatostatin analogue did not prolong the hypoglycemia-free interval. In nine patients with carcinoid syndrome, flushing was uniformly controlled with 50 [mu]g of SMS 201-995 administered every eight to 12 hours. One of the nine required exocrine pancreatic replacement. After six months of treatment, three of the nine had no change in tumor size and one had remission of symptoms and stopped treatment. In two patients with vipoma, SMS 201-995 controlled diarrhea and reduced levels of vasoactive intestinal peptide; tumor necrosis occurred in one patient. In a patient with diabetic diarrhea unresponsive to all treatments, SMS 201-995 therapy controlled the diarrhea but did not interfere with control of the diabetes. | en_US |
dc.format.extent | 6719400 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes, | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Family Medicine and Primary Care | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Endocrinology and Metabolism, and the Department of Surgery and Radiology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Endocrinology and Metabolism, and the Department of Surgery and Radiology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Endocrinology and Metabolism, and the Department of Surgery and Radiology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Endocrinology and Metabolism, and the Department of Surgery and Radiology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | no department found | en_US |
dc.contributor.affiliationother | no department found | en_US |
dc.identifier.pmid | 2879447 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/25940/1/0000002.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0002-9343(86)90582-6 | en_US |
dc.identifier.source | The American Journal of Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.